Bernstein raised the firm’s price target on CVS Health (CVS) to $87 from $86 and keeps a Market Perform rating on the shares following overall a very positive Investor Day event. The firm cites increased confidence in quality and depth of management teams, and reinforcement of the quality and market leadership of leading companies.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS:
